The founder of 23Andme, Anne Wojcicki, speaks during a supervision committee of the Government Supervision and Reform Chamber in Washington, DC, on June 10, 2025.
Andrew Harnik | Getty images
Anne Wojcicki, co -founder and former executive director of 23Andme, has regained control over the genetic test company in conflict after her new profit non -profit organization, Tam Research Institute, surpassed Regeneron PharmaceuticalsThe company announced Friday.
Tam will substantially acquire all 23Andme assets for $ 305 million, including its commercial lines of personal research and research services, as well as the Lemonaid Health Telesidia subsidiary. It is a great victory for Wojcicki, who resigned from his role as CEO when 23Andme requested the bankruptcy protection of chapter 11 in March.
Last month, Regeneron announced that it would buy most of the 23Andme assets for $ 256 million after it came out at the top during a bankruptcy auction. But Wojcicki presented a separate offer of $ 305 million through TTAM and pressed to reopen the auction. Tam is an acronym for the first 23Andme letters, according to the Wall Street Journal.
“I am delighted that the Tam Research Institute can continue the 23Andme mission to help people access, understand and benefit from the human genome,” Wojcicki said in a statement.
23Andme gained popularity due to their DNA test kits in the home that gave customers an idea of their family stories and genetic profiles. The five -time company CNB Disruptor 50 was made public in 2021 through a fusion with a special purpose acquisition company. At its peak, 23Andme was valued at around $ 6 billion.
The company struggled to generate recurring income and defense of viable research and therapy after going over, and has been plagued with privacy concerns since the computer pirates agreed to the information of almost seven million customers in 2023.
The acquisition of TTAM is still subject to the approval of the United States Banking Court for the Eastern District of Missouri.
